Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

End-Stage Renal Disease (ESRD)

Conditions

End-Stage Renal Disease (ESRD)

Trial Timeline

Aug 1, 2007 → Jan 1, 2010

NCT ID

NCT00548249

About Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate

Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate is a phase 2 stage product being developed by Rockwell Medical for End-Stage Renal Disease (ESRD). The current trial status is completed. This product is registered under clinical trial identifier NCT00548249. Target conditions include End-Stage Renal Disease (ESRD).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00548249	Phase 2	Completed	Aug 1, 2007	Jan 1, 2010	End-Stage Renal Disease (ESRD)

Competing Products

20 competing products in End-Stage Renal Disease (ESRD)

See all competitors

Product	Company	Stage	Hype Score
Conversion to Advagraf + conversion of non-immunosuppressant drugs to once daily + Conversion to once daily MPA	Astellas Pharma	Pre-clinical	23
donepezil HCl + donepezil HCl	Eisai	Approved	85
paricalcitol	AbbVie	Phase 3	77
daptomycin + daptomycin	Merck	Phase 1	33
Letermovir 480 mg [PREVYMIS]	Merck	Phase 1	33
MK-2060 + Placebo	Merck	Phase 2	52
Zepatier + Ribavirin + Sofosbuvir	Merck	Approved	85
MK-2060 + Placebo	Merck	Phase 1	33
daptomycin	Merck	Phase 1	33
MK-2060	Merck	Phase 1	33
MK-2060 + Placebo	Merck	Phase 1	33
Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab	Roche	Approved	85
Avacopan	Amgen	Phase 1	32
Ranolazine	Gilead Sciences	Approved	84
Bosutinib + Bosutinib + Bosutinib + Bosutinib	Pfizer	Phase 1	32
CP-690,550	Pfizer	Phase 1	32
Belatacept	Bristol Myers Squibb	Pre-clinical	22
Rabbit Anti-thymocyte Immunoglobulin + Tacrolimus + Methylprednisolone + Mycophenolate mofetil + Mycophenolate Na + prednisone	Sanofi	Approved	84
Single-dose rabbit Anti-thymocyte Globulin induction + Divided-dose rabbit Anti-thymocyte Globulin induction	Sanofi	Phase 2	51
rabbit anti-thymocyte globulin - single dose + mycophenolate mofetil + rabbit anti-thymocyte globulin - 4 doses + sirolimus + tacrolimus	Sanofi	Approved	84

Other Products from Rockwell Medical

Triferic AVNUApproved

TrifericPhase 3

Soluble Ferric Pyrophosphate (SFP)Phase 3

SFPPhase 3

Soluble Ferric Pyrophosphate (SFP)Phase 3